GLP1R and bone neoplasm: Intrathecal administration of GLP-1R agonists such as GLP-1(7–36) and exenatide alleviated hypersensitivity in models of formalin-induced, peripheral nerve injury-induced, bone cancer-induced, and diabetes-induced pain in mice and rats [31].